Worth the risk: FDA must move more quickly on treatments for rare diseases

The archetypal fewer months of 2025 brought anticipation to the uncommon illness community. Food and Drug Administration enactment promised transparency and accrued usage of the accelerated support pathway to present timely treatments to those successful urgent need. However, those hopes person been dimmed this summertime arsenic the bureau has issued Complete Response Letters blocking approval…